Korean J Physiol Pharmacol.  2022 Mar;26(2):135-144. 10.4196/kjpp.2022.26.2.135.

The antidiabetic drug rosiglitazone blocks Kv1.5 potassium channels in an open state

• Lee HM
• Hahn SJ
• Choi BH

• KMID: 2526732
• DOI: http://doi.org/10.4196/kjpp.2022.26.2.135

Abstract

An antidiabetic drug, rosiglitazone is a member of the drug class of thiazolidinedione. Although restrictions on use due to the possibility of heart toxicity have been removed, it is still a drug that is concerned about side effects on the heart. We here examined, using Chinese hamster ovary cells, the action of rosiglitazone on Kv1.5 channels, which is a major determinant of the duration of cardiac action potential. Rosiglitazone rapidly and reversibly inhibited Kv1.5 currents in a concentrationdependent manner (IC ₅₀ = 18.9 µM) and accelerated the decay of Kv1.5 currents without modifying the activation kinetics. In addition, the deactivation of Kv1.5 current, assayed with tail current, was slowed by the drug. All of the results as well as the usedependence of the rosiglitazone-mediated blockade indicate that rosiglitazone acts on Kv1.5 channels as an open channel blocker. This study suggests that the cardiac side effects of rosiglitazone might be mediated in part by suppression of Kv1.5 channels, and therefore, raises a concern of using the drug for diabetic therapeutics.

Keyword

Cardiotoxicity; Ion channel; Kv1.5 channel; Open channel block; Rosiglitazone